/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Castle Biosciences Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$39.41 0.0079(0.79%) CSTL at 04 Dec 2025 04:29 PM Diagnostics & Research
Lowest Today 38.7725
Highest Today 39.93
Today’s Open 39.53
Prev. Close 39.1
52 Week High 40.61
52 Week Low 14.59
Day’s Range: Low 38.7725 High 39.93
52-Week Range: Low 14.59 High 40.61
1 day return -
1 Week return -1.1
1 month return +24.67
3 month return +70.82
6 month return +131.64
1 year return +23.97
3 year return +61.32
5 year return -24.02
10 year return -

Institutional Holdings

BlackRock Inc 10.88

Vanguard Group Inc 7.48

Principal Financial Group Inc 6.20

Portolan Capital Management, LLC 5.14

Dimensional Fund Advisors, Inc. 4.75

Nuveen, LLC 3.70

Wasatch Advisors LP 3.62

Citadel Advisors Llc 3.06

Principal SmallCap R5 2.86

Vanguard Total Stock Mkt Idx Inv 2.85

BRAIDWELL LP 2.84

Principal U.S. Small Cap Equity 2.69

Allianz Asset Management AG 2.46

State Street Corp 2.44

iShares Russell 2000 ETF 2.38

Geode Capital Management, LLC 2.38

Renaissance Technologies Corp 2.31

Schroder Investment Management Group 2.24

Wasatch Ultra Growth 2.16

Strategic Advisers U.S. Total Stock 2.14

Palisade Capital Management LLc 1.98

CREF Stock R3 1.67

BlackRock Global Equity Mkt Netrl Instl 1.50

Millennium Management LLC 1.48

Wellington Management Company LLP 1.40

Bank of America Corp 1.32

Palisade Small Cap Core Equity 1.32

Ameriprise Financial Inc 1.28

UBS Group AG 1.25

Wasatch Micro Cap 1.24

Schroder US Smaller Companies Acc 1.10

Vanguard Institutional Extnd Mkt Idx Tr 1.07

Fidelity Small Cap Index 0.98

Vanguard Explorer Inv 0.95

DFA US Small Cap Value I 0.94

iShares Russell 2000 Value ETF 0.87

Buffalo Small Cap Growth 0.83

Kornitzer Small Cap Equity 0.83

Columbia Small Cap Value Discv A 0.82

Columbia Small Cap Value Discovery Fund 0.80

Market Status

Strong Buy: 8

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 1141.28 M

PB Ratio 2.4967

PE Ratio 0.0

Enterprise Value 915.68 M

Total Assets 531.24 M

Volume 301737

Company Financials

Annual Revenue FY23:192006000 192.0M, FY22:137039000 137.0M, FY21:94085000 94.1M, FY20:62649000 62.6M, FY19:51865000 51.9M

Annual Profit FY23:149927000 149.9M, FY22:105030000 105.0M, FY21:78263000 78.3M, FY20:52964000 53.0M, FY19:44555000 44.6M

Annual Net worth FY23:-75504000 -75.5M, FY22:-67138000 -67.1M, FY21:-31292000 -31.3M, FY20:-10284000 -10.3M, FY19:5277000 5.3M

Quarterly Revenue Q3/2025:83043000 83.0M, Q2/2025:86188000 86.2M, Q1/2025:87988000 88.0M, Q3/2024:85782000 85.8M, Q2/2024:87002000 87.0M

Quarterly Profit Q3/2025:64339000 64.3M, Q2/2025:68562000 68.6M, Q1/2025:71605000 71.6M, Q3/2024:70173000 70.2M, Q2/2024:69772000 69.8M

Quarterly Net worth Q3/2025:-501000 -0.5M, Q2/2025:4523000 4.5M, Q1/2025:-25848000 -25.8M, Q3/2024:2269000 2.3M, Q2/2024:8920000 8.9M

Fund house & investment objective

Company Information Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), uveal melanoma, and mental health conditions. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a risk stratification spatial-omics test to predict future development of progression of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide optimal drug treatment for patients diagnosed with major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. The company offers its products to skin cancer and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Organisation Diagnostics & Research

Employees 823

Industry Diagnostics & Research

CEO Mr. Derek J. Maetzold

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow